Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6142-6. doi: 10.1016/j.bmcl.2008.10.039. Epub 2008 Oct 11.

Abstract

Pyrrolo-pyrimidones of the general structure 1 were synthesized and evaluated for their potential as MK2 inhibitors. Potent derivatives were discovered which inhibit MK2 in the nanomolar range and show potent inhibition of cytokine release from LPS-stimulated monocytes. These derivatives were shown to inhibit phosphorylation of hsp27, a downstream target of MK2 and are modestly selective in a panel of 28 kinases.

MeSH terms

  • Arthritis, Rheumatoid / drug therapy
  • Combinatorial Chemistry Techniques
  • Cytokines / metabolism
  • Dose-Response Relationship, Drug
  • Drug Design
  • HSP27 Heat-Shock Proteins / antagonists & inhibitors
  • HSP27 Heat-Shock Proteins / metabolism
  • Humans
  • Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
  • Leukocytes, Mononuclear / drug effects
  • Lipopolysaccharides / pharmacology
  • Molecular Structure
  • Monocytes / drug effects
  • Phosphorylation
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Pyrimidinones / chemical synthesis*
  • Pyrimidinones / chemistry
  • Pyrimidinones / pharmacology*
  • Pyrroles / chemical synthesis*
  • Pyrroles / chemistry
  • Pyrroles / pharmacology*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors

Substances

  • Cytokines
  • HSP27 Heat-Shock Proteins
  • Intracellular Signaling Peptides and Proteins
  • Lipopolysaccharides
  • Pyrimidinones
  • Pyrroles
  • Tumor Necrosis Factor-alpha
  • MAP-kinase-activated kinase 2
  • Protein Serine-Threonine Kinases
  • p38 Mitogen-Activated Protein Kinases